NCT01363947 - Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 14, 2011

Primary Completion Date

June 3, 2016

Study Completion Date

June 3, 2016

Conditions

Non-Small Cell Lung Cancer, Ovarian Cancer

Interventions

DRUG

DNIB0600A

Several dose levels will be evaluated for DNIB0600A administered via IV infusion on Day 1 of each 21-day cycle until disease progression.

Trial Locations (7)

Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid

Sarah Cannon Research Inst., Nashville

Univ of Texas SW Medical Ctr, Dallas

HonorHealth Research Institute - Pima Center, Scottsdale

Smilow Cancer Hospital at Yale New Haven, New Haven

Hospital del Mar; Servicio de Oncologia, Barcelona

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona